| Study Acronym | LAMDARCT |
| Trial Title | L-DOPA for neovascular (wet) age-related macular degeneration (AMD)? A Randomised Controlled Trial: LAMDARCT |
| Clinical Area | Ophthalmology |
| Trial Status | Set Up |
| Chief Investigator (CI) | Professor Tunde Peto, Queen’s University Belfast |
| Sponsor | Belfast Health and Social Care Trust |
| Funder | National Institute for Health & Care Research |
For any queries regarding this trial please contact the study email (LAMDARCT@nictu.hscni.net) or call the NICTU (028 9615 1447).
-
Recruitment
Recruitment Target 360 Date Open to Recruitment Recruitment Date Closed to Recruitment -
Trial Design
Trial Design Prospective, randomised, pragmatic, multicentre, placebo-controlled clinical trial Study Aim Aim To assess the effectiveness and cost-effectiveness of L-DOPA in patients being treated for wet AMD.
Study Objectives
The specific objectives are to evaluate the effects of 24 months of L-DOPA in people newly diagnosed with wet AMD on:
1) Number of anti-VEGF injections
2) Distance and near visual acuity (VA)
3) Health-related and visual-related quality of life
4) Safety
5) Anatomical retinal findings indicative of disease activity
6) Costs and cost-effectiveness.
-
Chief Investigator (CI)
Chief Investigator Professor Tunde Peto, Queen’s University Belfast -
Sponsor(s) & Funder(s)
Sponsor Belfast Health & Social Care Trust Funder National Institute for Health & Care Research Award NIHR167468